Business Context and Reporting Period
Company: PHOTRONICS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: February 2, 1997
Business Overview: Photronics operates in the photomask manufacturing sector. The reporting period reflects significant expansion of international operations, including the start-up of a new facility in Singapore and acquisitions in Switzerland and the United Kingdom. The company adopted a 52-week fiscal year beginning in the first quarter of 1997.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Feb 2, 1997 | Three Months Ended Jan 31, 1996 |
|---|---|---|
| Net Sales | $40,029 | $34,668 |
| Gross Profit | $14,682 | $13,416 |
| Gross Margin | 36.7% | 38.7% |
| Operating Income | $7,345 | $7,006 |
| Net Income | $5,325 | $4,651 |
| Diluted EPS | $0.44 | $0.39 |
| Cash from Operations | $305 | $5,924 |
| Cash & Equivalents (End of Period) | $7,836 | $38,846 |
| Total Debt (Current + Long-term) | $2,044 | N/A (Not explicitly aggregated in text) |
Note: Gross Profit calculated as Net Sales minus Cost of Sales ($40,029 - $25,347 = $14,682; $34,668 - $21,252 = $13,416).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15.5% to $40.0 million. Over half of this increase was driven by new international manufacturing operations (Singapore, Switzerland, UK).
- Margin Compression: Gross margin decreased from 38.7% to 36.7%. This was attributed to the new international base not being fully utilized and higher labor/equipment costs associated with capacity expansion, partially offset by a favorable product mix of complex photomasks.
- Expense Increases:
- Selling, general, and administrative (SG&A) expenses rose 9.8% to $5.0 million but decreased as a percentage of sales (12.6% vs 13.2%).
- Research and development (R&D) expenses increased 26.1% to $2.3 million, reflecting focus on high-end technologies (phase shift, optical proximity correction, deep ultra-violet).
- Non-Operating Income: Interest and other income increased significantly to $1.3 million, primarily due to a $1.1 million gain on the sale of investment securities.
- Cash Flow: Net cash provided by operating activities dropped sharply to $305 from $5.9 million, largely due to a $6.2 million decrease in accounts payable and other liabilities. Net cash used in investing activities was $11.5 million, driven by $15.7 million in capital expenditures for equipment and construction.
Outlook, Risks, and Management Commentary
- Capital Expenditures: The company has outstanding commitments of approximately $62 million for additional manufacturing capacity and advanced R&D equipment. Management expects fixed operating costs to rise with continued expansion.
- Liquidity Strategy: Cash and short-term investments decreased by $13.7 million during the quarter. The company plans to finance future capital expenditures using working capital, bank lines of credit, and leasing arrangements. As of March 5, 1997, $3.0 million was outstanding on bank credit lines.
- Forward-Looking Risks: Management cites uncertainties in the market, pricing competition, procurement, and manufacturing efficiencies as potential risks that could cause actual results to differ from projections.
- Unusual Items: Net income included a one-time gain of $0.7 million ($0.05 per share) from the sale of investment securities.
Investor Verification Checklist
- Verify the utilization rates of the new Singapore, Switzerland, and UK facilities to assess the timeline for margin recovery.
- Confirm the status of the $62 million in outstanding capital expenditure commitments and the funding sources (debt vs. equity vs. cash).
- Monitor the trend in accounts payable, which decreased significantly in this quarter, to ensure it does not indicate strained supplier relationships or timing anomalies.
- Assess the sustainability of R&D spending growth (26.1% increase) relative to future revenue projections for high-end photomask technologies.
- Review the composition of "Investments and other assets" given the recent sale of securities and the fluctuation in fair value.